Advertisement

Extranodal Localization of Aggressive Lymphoma

  • Jeremy S. AbramsonEmail author
  • Armando López-Guillermo
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Aggressive lymphomas commonly involve both nodal and extranodal locations. DLBCL may primarily involve discrete extranodal locations and be characterized by distinct biology, clinical presentation, and treatment considerations. Though any extranodal site in the body may be involved by DLBCL, unique consideration is warranted for DLBCLs which primarily involve the GI tract, bone, mediastinum, testis, breast, and skin. These entities will be reviewed, including approach to staging, prognosis, and management, including the role of radiation therapy and CNS prophylaxis.

Keywords

Diffuse large B-cell lymphoma Extranodal lymphoma Primary bone lymphoma Primary testicular lymphoma Primary mediastinal B-cell lymphoma 

References

  1. 1.
    Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Norris HJ, Jensen RD. Relative frequency of ovarian neoplasms in children and adolescents. Cancer. 1972;30:713–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Konje JC, Otolorin EO, Odukoya OA, et al. Burkitts lymphoma of the ovary in Nigerian adults—a 27-year review. Afr J Med Med Sci. 1989;18:301–5.PubMedGoogle Scholar
  4. 4.
    Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin’s lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8:727–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin’s lymphomas. Part 2: head and neck, central nervous system and other less common sites. Ann Oncol. 1999;10:1023–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23:2797–804.PubMedCrossRefGoogle Scholar
  7. 7.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017.Google Scholar
  8. 8.
    d’Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin’s lymphomas. Danish LYFO Study Group. Eur J Cancer. 1991;27:1201–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–51.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Müller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin’s lymphomas (NHL): trends, geographic distribution, and aetiology. Ann Hematol. 2005;84:1–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Vannata B, Zucca E. Primary extranodal B-cell lymphoma: current concepts and treatment strategies. Chin Clin Oncol. 2015;4:10–27.PubMedGoogle Scholar
  12. 12.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  13. 13.
    Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefGoogle Scholar
  14. 14.
    Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Montalbán C, Díaz-López A, Dlouhy I, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176:918–28.PubMedCrossRefGoogle Scholar
  16. 16.
    Besson C, Lancar R, Prevot S, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS. 2017;31:2493–501.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Al Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefGoogle Scholar
  18. 18.
    Copie-Bergman C, Gaulard P, Leroy K, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27:5573–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021–31.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130:590–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–62.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.PubMedCrossRefGoogle Scholar
  25. 25.
    d’Amore F, Brincker H, Gronbaek K, et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 1994;12:1673–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Kock P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered by the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3861–73.CrossRefGoogle Scholar
  27. 27.
    Howell JM, Auer-Grzesiak I, Zhang J, et al. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin’s lymphoma in a North American population. Can J Gastroenterol. 2012;26:452–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferreri A, Freschi M, Dell’Oro S, et al. Prognostic significance of the histopathologic recognition of low- and high-grade components in stages I-II B-cell gastric lymphomas. Am J Surg Pathol. 2001;25:95–102.PubMedCrossRefGoogle Scholar
  30. 30.
    Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphomas 2011 part I: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Dickson BC, Serra S, Chetty R. Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasm. Expert Rev Anticancer Ther. 2006;6:1609–28.PubMedCrossRefGoogle Scholar
  32. 32.
    Ikoma N, Badgwell BD, Mansfield PF. Multimodality treatment of gastric lymphoma. Surg Clin North Am. 2017;97:405–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Martinelli G, Gigli F, Calabrese L, et al. Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (IELSG 4). Leuk Lymphoma. 2009;50:925–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Chen LT, Lin JT, Shyu RY, et al. Prospective study of helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Ferreri AJ, Govi S, Raderer M, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood. 2012;120:3858–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Kuo SH, Yeh KH, Wu M, et al. Helicobacter pylori eradication therapy is effective in the treatment of early stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Cuccurullo R, Govi S, Ferreri AJ. De-escalating therapy in gastric aggressive lymphoma. World J Gastroenterol. 2014;20:8993–7.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Kuo SH. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:e220.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Cortelazzo S, Rossi A, Oldani F, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol. 2002;118:218–28.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Ibrahim EM, Ezzat AA, El-Weshi AN, et al. Primary intestinal diffuse large B-cell non-Hodgkin’s lymphoma: clinical features, management, and prognosis of 66 patients. Ann Oncol. 2001;12:53–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Dreyling M. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book. 2014:191–8.CrossRefGoogle Scholar
  42. 42.
    Shannon EM, MacQueen IT, Miller JM, et al. Management of primary gastrointestinal non-Hodgkin lymphomas: a population-based survival analysis. J Gastrointest Surg. 2016;20:1141–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin North Am. 2016;30:1333–43.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012;25:101–17.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Hoelzer D. Dose-adjusted EPOCH-R for Burkitt lymphoma. Clin Adv Hematol Oncol. 2014;12:777–9.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117:6756–67.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92:706–15.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig Rep. 2016;11:504–13.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T-cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Messina C, Ferreri AJ, Govi S, et al. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the International Extranodal Lymphoma Study Group (the IELSG 14 study). Br J Haematol. 2014;164:834–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Bruno Ventre M, Ferreri AJ, Gospodarowicz M, et al. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist. 2014;19:291–8.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Horsman JM, Thomas J, Hough R, et al. Primary bone lymphoma: a retrospective analysis. Int J Oncol. 2006;28:1571–5.PubMedGoogle Scholar
  53. 53.
    Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term, follow-up of 82 patients. Cancer. 2006;106:2652–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.PubMedCrossRefGoogle Scholar
  55. 55.
    Govi S, Christie D, Messina C, et al. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. Ann Oncol. 2014;25:176–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115–22.PubMedCrossRefGoogle Scholar
  57. 57.
    Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. (revised) ed. Lyon: International Agency for Research on Cancer; 2017. p. 314–6.Google Scholar
  61. 61.
    Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372–6.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)gallium scan in 50 patients. Blood. 1999;94:3289–93.PubMedGoogle Scholar
  63. 63.
    Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123–30.PubMedCrossRefGoogle Scholar
  64. 64.
    Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55:538–43.PubMedCrossRefGoogle Scholar
  65. 65.
    Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group Study. Ann Oncol. 2011;22:664–70.PubMedCrossRefGoogle Scholar
  66. 66.
    Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15:1646–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:1329–36.PubMedCrossRefGoogle Scholar
  69. 69.
    Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129:2328–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267–70.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227–32.PubMedCrossRefGoogle Scholar
  74. 74.
    Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88:154–61.PubMedCrossRefGoogle Scholar
  76. 76.
    Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–81.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol. 2008;216:209–17.PubMedCrossRefGoogle Scholar
  79. 79.
    Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766–72.PubMedCrossRefGoogle Scholar
  80. 80.
    Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161–6.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–90.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–66.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–6.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129:3071–3.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev. 2014;40:900–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Jia Y, Sun C, Liu Z, et al. Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. Oncotarget. 2017;9:3956–67.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Franco F, González-Rincón J, Lavernia J, et al. Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget. 2017;8:102888–97.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Avilés A, delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69:256–60.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Lin Y, Guo XM, Shen KW, et al. Primary breast lymphoma: long-term treatment outcome and prognosis. Leuk Lymphoma. 2006;47:2102–9.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19:233–41.PubMedCrossRefGoogle Scholar
  91. 91.
    Liu PP, Wang KF, Jin JT, et al. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the rituximab era: a SEER database analysis. Cancer Med. 2018;7:1845–51.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Willemze R, Vergier B, Duncan LM. Primary cutaneous diffuse large B-cell lymphoma, leg type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, MM LB, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017. p. 303–4.Google Scholar
  93. 93.
    Hamilton SN, Wai ES, Tan K, et al. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys. 2013;87:719–25.PubMedCrossRefGoogle Scholar
  94. 94.
    Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150:535–41.PubMedCrossRefGoogle Scholar
  95. 95.
    Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–6.CrossRefGoogle Scholar
  96. 96.
    Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31:37–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Massachusetts General Hospital Cancer CenterBostonUSA
  2. 2.Hospital ClínicIDIBAPSBarcelonaSpain

Personalised recommendations